News
2d
Sportschosun on MSNDo Kyung-wan 'Hurry up and quit!'Why did you recommend Lim Hyun-joo to make a pre-declaration?Announcer Lim Hyun-joo will appear on entertainment shows for the first time since giving birth to her second child. In the 19th episode of the ENA entertainment program 「My Child's Private Life」, ...
President Trump is switching up his messaging on the economy amid growing concern from voters and even fellow Republicans ...
Eli Lilly stock has been a big-time winner over the last couple of years, but looming tariffs are worrying some investors. The pharmaceutical sector could be the next industry to face sweeping ...
A new daily weight-loss pill could be just as effective as the popular injectables that help patients lower their blood sugar and lose unwanted weight. "I think we're really at the beginning of a ...
Eli Lilly is getting closer to bringing a weight loss pill to market, but CEO David Ricks notes certain factors need to be considered to prevent prices from ballooning. The Trump administration ...
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%. Last year was a transformative year for the Indianapolis-based pharmaceutical giant ...
Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other other firms that ended the week strong. The stock market ended the shortened trading ...
Eli Lilly said its experimental pill met its goals in a pivotal study, helping diabetes patients lower blood sugar—and even reduce weight, bringing an oral version of the booming class of drugs ...
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results